Detalhe da pesquisa
1.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569872
2.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369086
3.
Risk of secondary progressive multiple sclerosis after early worsening of disability.
J Neurol Neurosurg Psychiatry
; 94(12): 984-991, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414538
4.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
J Neurol Neurosurg Psychiatry
; 94(1): 23-30, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171104
5.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068931
6.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414534
7.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Mult Scler
; 29(2): 221-235, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433775
8.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
; 29(7): 875-883, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36851894
9.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36800908
10.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692895
11.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler
; 28(11): 1752-1761, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373638
12.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol
; 29(8): 2321-2334, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35582938
13.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423618
14.
Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis.
Eur J Neurol
; 28(3): 901-909, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326677
15.
Hallmarks of spinal cord pathology in multiple sclerosis.
J Neurol Sci
; 456: 122846, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142540
16.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
J Neurol
; 271(1): 472-485, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768389
17.
Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study.
Mult Scler Relat Disord
; 79: 104994, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683557
18.
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Neurodegener Dis Manag
; 13(4): 215-221, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287269
19.
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
JAMA Neurol
; 80(7): 739-748, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273217
20.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
; 80(7): 702-713, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437240